Xuyang Zhao

Xuyang Zhao

Auto-generated profile, based on publicly available information

Xuyang Zhao

Institute of Systems Biomedicine, Department of Immunology, School of Basic Medical Sciences, Beijing Key Laboratory of Advanced Pharmaceutical Preparation, Peking University, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2020 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
DLDan Lu
Dan Lu
LLLiang Liu
Liang Liu
YSYizhe Sun
Yizhe Sun
JSJia Song
Jia Song
QYQi Yin
Qi Yin
YYYuxin Yin
Yuxin Yin

24 December 2021 in Science Advances
Verified
Journal Article
Open access
GWGuangxi Wang
Guangxi Wang
HYHantao Yao
Hantao Yao
YGyan gong
yan gong
ZLZipeng Lu
Zipeng Lu
RPRuifang Pang
Ruifang Pang
YYYuxin Yin
Yuxin Yin
The machine learning–aided serum lipidomics approach could be used to help early diagnosis of patients with PDAC.

19 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJia Song
Jia Song
WZWei Zhao
Wei Zhao
XZXin Zhang
Xin Zhang
WTWenyu Tian
Wenyu Tian
XZXuyang Zhao
Xuyang Zhao
DLDan Lu
Dan Lu
RIG-I/DDX58 plays a key role in host innate immunity. However, its therapeutic potential for inflammation-related cancers remains to be explored. Here we identify frameshift germline mutations of RIG-I occurring in patients with colon cancer. Accordingly, Rig-ifs/fs mice bearing a frameshift mutant Rig-i exhibit increased susceptibility to colitis-related colon cancer as well as enhanced inflammatory response to chemical, virus or bacteria. In addition to interruption of Rig-i mRNA translation, the Rig-i mutation changes the secondary structure of Rig-i pre-mRNA and impairs its association with DHX9, consequently inducing a circular RNA generation from Rig-i transcript, thereby, designated as circRIG-I. CircRIG-I is frequently upregulated in colon cancers and its upregulation predicts poor outcome of colon cancer. Mechanistically, circRIG-I interacts with DDX3X, which in turn stimulates MAVS/TRAF5/TBK1 signaling cascade, eventually activating IRF3-mediated type I IFN transcription and aggravating inflammatory damage. Reciprocally, all-trans retinoic acid acts as a DHX9 agonist, ameliorates immunopathology through suppression of circRIG-I biogenesis. Collectively, our results provide insight into mutant RIG-I action and propose a potential strategy for the treatment of colon cancer.

23 March 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
QZQiaoling Zhang
Qiaoling Zhang
HLHui Liang
Hui Liang
XZXuyang Zhao
Xuyang Zhao
LZLin Zheng
Lin Zheng
YLYunqiao Li
Yunqiao Li
YYYuxin Yin
Yuxin Yin
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 January 2021 in Redox Biology
Verified
Journal Article
Open access
MZMeng Zhang
Meng Zhang
JGJianing Gao
Jianing Gao
XZXuyang Zhao
Xuyang Zhao
MZMingming Zhao
Mingming Zhao
DMDong Ma
Dong Ma
Lemin ZhengLemin Zheng
Lemin Zheng
Macrophages regulate the inflammatory response and affect re-endothelialization. Inflammation and macrophages play important roles in promoting tissue repair, but p38α mitogen-activated protein kinase's role in re-endothelialization is unknown. Wire injuries of carotid arteries and Evans blue staining were performed in macrophage-specific p38α-knockout (p38αfl/flLysMCre+/-) mice and control mice (p38αfl/fl). Re-endothelialization of the carotid arteries at 3, 5 and 7 days was significantly promoted in p38αfl/flLysMCre+/- mice. In vitro experiments indicated that both the proliferation and migration of endothelial cells were enhanced in conditioned medium from peritoneal macrophages of p38αfl/flLysMCre+/- mice. Interleukin-6 (IL-6) level was decreased significantly in macrophages of p38αfl/flLysMCre+/- mice and an IL-6-neutralizing antibody promoted endothelial cell migration in vitro and re-endothelialization in p38αfl/fl mice in vivo. Phosphoproteomics revealed that the phosphorylation level of S544/T545/S549 sites in megakaryocytic leukemia 1 (MKL1) was decreased in p38αfl/flLysMCre+/- mice. The mutation of either S544/S549 or T545/S549 sites could reduce the expression of IL-6 and the inhibition of MKL1 reduced the expression of IL-6 in vitro and promoted re-endothelialization in vivo. p38α in macrophages aggravates injury of arteries by phosphorylating MKL1, and increasing IL-6 expression after vascular injury.

23 August 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
XZXin Zhang
Xin Zhang
LGLimei Guo
Limei Guo
WTWenyu Tian
Wenyu Tian
YYYing Yang
Ying Yang
YYYue Yin
Yue Yin
DLDan Lu
Dan Lu
Local recurrence and distal metastasis negatively impact the survival and quality of life in patients with papillary thyroid cancer (PTC). Therefore, identifying potential biomarkers and therapeutic targets for PTC is clinically crucial. In this study, we performed a multiomics analysis that identified a subset of CD36+ proinflammatory macrophages within the tumor microenvironment of PTC. The recruitment of CD36+ macrophages to premalignant regions strongly correlated with unfavorable outcomes in PTC, and the presence of tumor-infiltrating CD36+ macrophages was determined to be a risk factor for recurrence. The CD36+ macrophages exhibited interactions with metabolically active ZCCHC12+ tumor cells. By secreting SPP1, the CD36+ macrophages activated the PI3K-AKT signaling pathway, thereby promoting proliferation of the cancer cells. Dysregulation of iodine metabolism was closely related to the acquisition of the pro-inflammatory phenotype in macrophages. Iodine supplementation inhibited the activation of proinflammatory signaling and impeded the development of CD36+ macrophages by enhancing DUSP2 expression. Overall, our findings shed light on the intricate cross-talk between CD36+ macrophages and ZCCHC12+ tumor cells, providing valuable insights for the treatment and prognosis of PTC.